BURNABY, BRITISH COLUMBIA--(Marketwired - April 3, 2014) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD)(OTCQX:LEDIF)(FRANKFURT:LME) ("LED Medical" or the "Company") announced today that LED Imaging, the new dental imaging division of its wholly-owned operating subsidiary, LED Dental Ltd. ("LED Dental") has partnered with Ray Co., Ltd. ("Ray Co."), a subsidiary of Samsung, to sell, install and provide support for the RAYSCAN α - Expert dental imaging system.
The RAYSCAN α - Expert is a multi-function digital extraoral imaging system with 3D cone beam computed tomography (CBCT), panoramic and cephalometric capabilities. Ray Co. is the first partner to join LED Imaging's product portfolio since the company announced its expansion into the dental imaging category and emergent product offerings.
"We are very excited about working with Ray Co. and Samsung to provide practitioners with a compact, yet powerful, CBCT imaging system to capture the crisp, high-quality images needed for diagnosis and treatment," said Lamar Roberts, president of LED Imaging. "We understand what practitioners want and need, so partnerships like this give us an advantage to provide the best technology available in each product category."
The RAYSCAN α - Expert's 3D images are captured using an optimal 9 cm x 9 cm field of view, which is ideal for a wide variety of clinical applications. The system's CMOS and Direct Deposition Cesium Iodide (CsI) Detector ensure practitioners can quickly capture high-quality, 16-bit DICOM images at a low radiation dose. To minimize error from patient positioning and movement, the system's focal trough is stabilized and controlled through Adaptive Moving Focus technology. The RAYSCAN α's exclusive denoising technology enhances image quality by removing noise that would otherwise blur the image.
Due to its sleek design, the RAYSCAN α - Expert can fit into nearly any practice floor plan. The system's height adjustment component means patients of all sizes, including those in wheelchairs, can fit comfortably in the unit. The RAYSCAN α - Expert is also the world's first imaging system to utilize a wireless remote control for patient positioning. Additionally, green, blue, yellow and red LED lights indicate the status of the unit to practitioners at a glance: ready, standby, exposure and emergency. These components led to the RAYSCAN α - Expert receiving both the red dot design award and International Design Excellence Bronze Award for its effective product design.
In addition to the RAYSCAN α - Expert's advanced imaging capabilities and unique design, the system also features an intuitive user interface to streamline the capture process and simplify the manipulation of images. The system utilizes Xelis 3D Imaging Software, which features state-of-the art functionality and a comprehensive implant planning module.
"With the legal close of our business partnership with LED Imaging, we're one step closer to bringing oral health practitioners a strong manufacturer that offers greater dental products and access to more services in the U.S. market," said Dr. Sangchul Lee, CEO of Ray Co. "As such, we're proud to align our product with the LED Imaging brand due to its solid leadership team with both clinical and industry experience."
Ray Co. is Samsung's first subsidiary business venture in the dental technology industry. Samsung is a worldwide leader in technology and electronics. LED Imaging will offer nationwide service and technical support for the RAYSCAN α - Expert. To learn more about LED Imaging, visit www.leddental.com.
About Ray Co., Ltd., a Subsidiary of Samsung
Since 2004, Ray Co., Ltd., has specialized in researching, developing and producing high-quality 3D computed tomography systems for the medical and dental industries. Due to outstanding x-ray technology development, Ray Co. became a subsidiary of worldwide technology leader SAMSUNG Electronics Co., Ltd, in 2010. With Samsung's full support on design, manufacturing and quality management, Ray Co. launched the RAYSCAN α - Expert in 2012. The company strives for differentiation in the dental industry through relentless R&D to deliver imaging products based on a unique design concept: simple + smart + emotional.
About LED Dental Ltd.
Based in Atlanta, Ga., LED Dental Ltd. is a wholly‐owned subsidiary of LED Medical Diagnostics Inc. Backed by an experienced leadership team dedicated to a higher level of service and support, LED Dental offers advanced diagnostic imaging equipment that seamlessly integrates into dental practices. The Company is committed to providing dental practitioners with the best technology available by identifying and adding strong products to its growing portfolio. Additionally, the company manufactures the award-winning VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. The VELscope® Vx is now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. For more information, call 888.541.4614 or visit www.leddental.com.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED‐based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX‐V) under the symbol "LMD," the OTCQX under the symbol "LEDIF," as well as the Frankfurt Stock Exchange under the symbol "LME." For more information, visit www.ledmd.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future distribution strategy and product offerings and the potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies to the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.